QL-X-138

QL-X-138 is a potent and selective BTK/MNK dual kinase inhibitor, exhibits covalent binding to BTK and non-covalent binding to MNK. QL-X-138 shows IC50s of 9.4 nM, 107.4 nM and 26 nM for BTK, MNK1 and MNK2 kinases respectively. QL-X-138 also shows anti-dengue virus 2 activity, with an IC50 of 3.5 μM. QL-X-138 can be used for the research of B-cell malignancies[1][2].

Product Specifications

CAS Number

[1469988-63-3]

UNSPSC

12352005

Target

Btk; Dengue Virus; Flavivirus; MNK

Type

Reference compound

Related Pathways

Anti-infection; MAPK/ERK Pathway; Protein Tyrosine Kinase/RTK

Applications

COVID-19-anti-virus

Field of Research

Cancer; Infection

Assay Protocol

https://www.medchemexpress.com/ql-x-138.html

Purity

99.77

Solubility

DMSO : 25 mg/mL (ultrasonic; warming; heat to 80°C)

Smiles

C=CC(NC1=CC(N2C(C=CC3=C2C4=CC(C5=CNN=C5)=CC=C4N=C3)=O)=CC=C1C)=O

Molecular Formula

C25H19N5O2

Molecular Weight

421.45

References & Citations

[1]Wu H, et, al. Discovery of a BTK/MNK dual inhibitor for lymphoma and leukemia. Leukemia. 2016 Jan;30 (1) :173-81.|[2]Wispelaere M, et, al. Discovery of host-targeted covalent inhibitors of dengue virus. Antiviral Res. 2017 Mar;139:171-179.